Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 8/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357820 | 0.74 | TDP1 (0.44) | TDP1STK17BSTK17AMEN1GAA | |
| SCHEMBL7963556 | 0.73 | CAMK2D (0.46) | TDP1MEN1GAAKMT2ACAMK2D | |
| SCHEMBL344732 | 0.73 | CA12 (0.37) | TDP1MEN1GAAKMT2ADRD2 | |
| SCHEMBL21069375 | 0.72 | STK17B (0.44) | TDP1STK17BSTK17AMEN1GAA | |
| SCHEMBL25381100 | 0.71 | CAMK2D (0.48) | TDP1MEN1GAAKMT2ADRD2 | |
| SCHEMBL3387585 | 0.71 | DRD2 (0.47) | TDP1MEN1GAAKMT2ADRD2 | |
| SCHEMBL22366404 | 0.70 | TDP1 (0.46) | TDP1STK17BSTK17AMEN1GAA | |
| SCHEMBL3020258 | 0.70 | TDP1 (0.81) | TDP1STK17BSTK17AMEN1GAA | |
| SCHEMBL569251 | 0.70 | TDP1 (0.74) | TDP1STK17BSTK17AMEN1GAA | |
| SCHEMBL3154615 | 0.70 | TDP1 (0.51) | TDP1MEN1GAAKMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338467-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058293-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2274306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009114566-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | TDP1 3952/4885STK17B 3365/4885STK17A 3911/4885 |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | TDP1 3952/4885STK17B 3365/4885STK17A 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.